Clinical and Economic Aspects of <i>KRAS </i>Mutational Status as Predictor for Epidermal Growth Factor Receptor Inhibitor Therapy in Metastatic Colorectal Cancer Patients

Robert Königsberg(Kaiser-Franz-Josef-Spital), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy), Wilfried Büchler(Kaiser-Franz-Josef-Spital), Wolfgang Hulla(Fachhochschule Wiener Neustadt), Robert Terkola(Kaiser-Franz-Josef-Spital), Angelika Reiner‐Concin(Donauspital), Tanja Steininger(Kaiser-Franz-Josef-Spital), M. Klimpfinger(Kaiser-Franz-Josef-Spital)
Oncology
January 1, 2011
10.1159/000334919
Cited by 13

Related Papers

Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
|Blood|2000|322
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients
|Acta Oncologica|2011|239
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
|Journal of Clinical Oncology|2008|226
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
|Journal of Clinical Oncology|2011|222
Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib
|Radiology|2012|197